Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GOSSNASDAQ:LABPNASDAQ:PRTANASDAQ:RNAC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGOSSGossamer Bio$1.24-2.4%$1.05$0.51▼$1.55$281.85M1.851.51 million shs1.13 million shsLABPLandos Biopharma$22.93+0.6%$22.54$2.50▼$22.94$71.77M0.1419,700 shs50,800 shsPRTAProthena$5.08+0.2%$7.61$4.32▼$25.42$273.44M-0.08718,233 shs806,353 shsRNACCartesian Therapeutics$10.42+1.8%$10.58$8.46▼$29.65$270.44M0.3387,771 shs45,404 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGOSSGossamer Bio-1.55%+0.79%+16.51%-12.41%+144.04%LABPLandos Biopharma0.00%0.00%0.00%0.00%0.00%PRTAProthena-0.59%+0.20%-33.20%-63.10%-76.40%RNACCartesian Therapeutics-1.63%+9.64%+0.39%-35.19%-65.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGOSSGossamer Bio3.8252 of 5 stars3.51.00.04.72.91.70.0LABPLandos BiopharmaN/AN/AN/AN/AN/AN/AN/AN/APRTAProthena3.8395 of 5 stars4.24.00.00.02.81.71.3RNACCartesian Therapeutics1.9084 of 5 stars3.40.00.00.02.93.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGOSSGossamer Bio 3.00Buy$7.75525.00% UpsideLABPLandos Biopharma 0.00N/AN/AN/APRTAProthena 2.33Hold$31.50520.08% UpsideRNACCartesian Therapeutics 2.71Moderate Buy$43.00312.67% UpsideCurrent Analyst Ratings BreakdownLatest LABP, GOSS, PRTA, and RNAC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025PRTAProthenaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.005/27/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/16/2025GOSSGossamer BioThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $8.005/16/2025GOSSGossamer BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.005/13/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGOSSGossamer Bio$124.59M2.26N/AN/A$0.28 per share4.43LABPLandos Biopharma$18M3.99N/AN/A$7.41 per share3.09PRTAProthena$137.94M1.98N/AN/A$10.46 per share0.49RNACCartesian Therapeutics$34.17M7.91N/AN/A($82.38) per share-0.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGOSSGossamer Bio-$179.82M-$0.23N/AN/AN/AN/A-127.28%-22.12%8/11/2025 (Estimated)LABPLandos Biopharma-$21.93M-$3.99N/AN/AN/AN/A-73.00%-63.00%N/APRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%8/6/2025 (Estimated)RNACCartesian Therapeutics-$219.71M-$52.83N/AN/AN/A-510.72%N/A-6.03%8/6/2025 (Estimated)Latest LABP, GOSS, PRTA, and RNAC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GOSSGossamer Bio-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million5/8/2025Q1 2025RNACCartesian Therapeutics-$0.61-$0.68-$0.07-$0.68$0.69 million$1.10 million3/18/2025Q4 2024GOSSGossamer Bio-$0.15-$0.15N/A-$0.15$7.02 million$9.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGOSSGossamer BioN/AN/AN/AN/AN/ALABPLandos BiopharmaN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGOSSGossamer Bio3.646.746.74LABPLandos BiopharmaN/A4.434.43PRTAProthenaN/A11.5211.52RNACCartesian TherapeuticsN/A10.7010.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGOSSGossamer Bio81.23%LABPLandos Biopharma49.06%PRTAProthena97.08%RNACCartesian Therapeutics86.95%Insider OwnershipCompanyInsider OwnershipGOSSGossamer Bio6.70%LABPLandos Biopharma1.30%PRTAProthena9.20%RNACCartesian Therapeutics60.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGOSSGossamer Bio180227.30 million215.27 millionOptionableLABPLandos Biopharma193.13 million3.09 millionNot OptionablePRTAProthena13053.83 million38.64 millionOptionableRNACCartesian Therapeutics6425.95 million10.70 millionOptionableLABP, GOSS, PRTA, and RNAC HeadlinesRecent News About These CompaniesEquities Analysts Offer Predictions for RNAC FY2026 EarningsJune 11 at 2:35 AM | americanbankingnews.comCantor Fitzgerald Comments on RNAC FY2026 EarningsJune 10 at 8:30 AM | marketbeat.comNuveen Asset Management LLC Buys 47,889 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC)June 5, 2025 | marketbeat.comCartesian Therapeutics Announces New Employment Inducement GrantsJune 3, 2025 | globenewswire.comBTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)June 2, 2025 | theglobeandmail.comCartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia GravisMay 30, 2025 | globenewswire.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Lifted by Northern Trust CorpMay 28, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Forecast for RNAC EarningsMay 23, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for RNAC Q1 Earnings?May 22, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 22, 2025 | marketbeat.comCitadel Advisors LLC Has $5.64 Million Stake in Cartesian Therapeutics, Inc. (NASDAQ:RNAC)May 20, 2025 | marketbeat.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Bought by MPM Bioimpact LLCMay 16, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Estimate for RNAC EarningsMay 16, 2025 | marketbeat.comCartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQMay 13, 2025 | manilatimes.netAnalysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)May 11, 2025 | theglobeandmail.comCartesian Therapeutics (RNAC) Gets a Buy from Mizuho SecuritiesMay 11, 2025 | theglobeandmail.comCartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 11, 2025 | finance.yahoo.comCartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comWhy Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside PotentialMay 5, 2025 | insidermonkey.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 2, 2025 | globenewswire.comCartesian Therapeutics management to meet with BTIGApril 26, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLABP, GOSS, PRTA, and RNAC Company DescriptionsGossamer Bio NASDAQ:GOSS$1.24 -0.03 (-2.36%) Closing price 04:00 PM EasternExtended Trading$1.24 0.00 (0.00%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.Landos Biopharma NASDAQ:LABPLandos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.Prothena NASDAQ:PRTA$5.08 +0.01 (+0.20%) Closing price 04:00 PM EasternExtended Trading$5.08 0.00 (0.00%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Cartesian Therapeutics NASDAQ:RNAC$10.42 +0.18 (+1.76%) Closing price 04:00 PM EasternExtended Trading$10.44 +0.02 (+0.14%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
